NASDAQ · Biotechnology
ARCT (ARCT) Stock
$6.26
+0.64%
NASDAQ: ARCT
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Zacks · Jul 3, 2026
Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis
MT Newswires · Jul 2, 2026
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Business Wire · Jul 2, 2026
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
MarketBeat · Jun 5, 2026
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
Moby · May 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.99%
Institutions Held80.45%
Institutions Float Held87.43%
Peer Comparison
About ARCT
ARCT is led by CEO Joseph E. Payne, employs 174 people, headquartered in US, publicly traded since 2013.
ARCT stock trades at $6.26 with a market capitalization of $177.93M. The stock is valued at a price-to-earnings (P/E) ratio of -2.93, price-to-book of 0.93, price-to-sales of 4.41. Over the past 52 weeks the stock has ranged between $5.53 and $24.17, and currently trades 74.1% below its 52-week high.
On profitability, ARCT generates a return on equity (ROE) of -30.84%, return on capital employed of -35.05%, an operating margin of -111.94%, a net profit margin of -1.73%.